Mankind Pharma Q2 Results 2023

Read this story to learn about Q2- highlights, performance, earnings, dividend updates, market performance, etc.,

Highlights of the Result

· The Revenues for Q2 FY’24 stood at ₹ 2,708 Cr · Net profit for Q2 FY’24 stood at ₹ 511 Cr · EBITDA is at ₹ 686 Cr, up by 15% YoY

Performance Highlights

· The Revenue grew a 12% YoY · Profit after tax (PAT) saw an increment of 21% YoY · Domestic revenue increased by 7%, while export revenue surged 159% YoY

Steady Performance

The performance of Q2 continues its steady trajectory with Revenue/EBITDA and PAT showing growth by 12%/15% and 21% YoY, respectively.

Business Highlights

Mankind Pharma is 4th in market share at 4.4%. It outperforms in chronic growth, increases prescriber penetration, and enhances exports with a 159% YoY growth, targeting emerging markets and differentiated filings.